Monitor the commercial launch timeline in H1 2027 and initial adoption rates. The tubeless feature with 7-day wear is a competitive differentiator against other tubeless pumps. Watch for competitor responses and any supply or manufacturing scale-up risks noted in the forward-looking statements.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $20.07entry
- T+1 · 21h ago −7.92%α −6.01% · $18.48
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tandem Diabetes Care received FDA 510(k) clearance for a tubeless cartridge and infusion set for its Tandem Mobi insulin pump, enabling up to 7 days of wear. Commercial launch is planned for the first half of 2027 in the U.S. This expands the product's addressable market by offering a tubeless option alongside the existing tubed configuration.
Key Facts
- Received FDA 510(k) clearance for Tandem Mobi tubeless cartridge and infusion set on November 12, 2026.
- Tubeless infusion set cleared for up to 7 days of wear; cartridge cleared for 3 days of use.
- Full commercial launch planned for first half of 2027 in the United States.
- Tandem Mobi pump is now cleared for both tubeless and tubed infusion options.
- The system incorporates Control-IQ+ advanced hybrid closed-loop technology.
Financial Impact
Regulatory clearance for a differentiated tubeless product expands Tandem's addressable market in insulin delivery. No financial figures were provided in the filing.
Risk Factors
- Commercial launch is not until H1 2027, with no revenue contribution in the near term.
- Supply and manufacturing scale-up risks could delay launch or limit initial availability.
- Competitor products with similar tubeless automated insulin delivery features may erode market share.
- Regulatory clearance must be maintained; any safety or quality issues could impact the product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001438133-26-000148 |
| Document: 0001438133-26-000148-index-headers.html | 0001438133-26-000148 |
| Document: 0001438133-26-000148-index.html | 0001438133-26-000148 |
| Document: 0001438133-26-000148.txt | 0001438133-26-000148 |
Track record
9 reports on TNDM
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $18.50 Now $18.48 +0.11% settles Nov 18
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $20.00 Now $18.48 −7.60% settles Nov 17
- Nov 13, 20263d ago 8-K Bullish 5/10 Viewing Entry $20.07 to $18.48 Now $18.48 −7.92% ▼ −7.92% −6.01% vs SPY
- Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $18.71 to $18.77 Now $18.48 −1.23% ▲ +0.32% −1.00% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $16.91 to $18.17 Now $18.48 +9.28% ▲ +7.45% +5.08% vs SPY
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $19.68 to $19.79 Now $18.48 −6.10% ▲ +0.56% +0.94% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $15.80 to $16.60 Now $18.48 +16.96% ▲ +5.06% +4.52% vs SPY
- May 15, 202626w ago 8-K Neutral 3/10 Entry $12.82 to $13.53 Now $18.48 +44.15% ▲ +5.54% +5.60% vs SPY
- Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $19.35 to $19.68 Now $18.48 −4.50% ▲ +1.71% +1.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers